Magenta Therapeutics Stock
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Sign up today and learn more about Magenta Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Magenta Therapeutics Stock
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Funding History
| November 2016 | $48.5M |
|---|---|
| May 2017 | $50.0M |
| April 2018 | $52.0M |
Management
CSO
Michael Cooke
VP and Head of Business Development
Christina Isacson
CEO, President & Co-Founder
Jason Gardner
COO
Bastiano Sanna
Press
Business Wire (press release) - Jun, 25 2018
Magenta Therapeutics Announces Closing of Initial Public OfferingStockNewsTimes - Jun, 24 2018
Magenta Therapeutics (NASDAQ:MGTA) to Raise $100 Million in IPOEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
